triazoles has been researched along with bosutinib in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Boysen, J; Ghosh, AK; Kay, NE; Mukhopadhyay, D; Sassoon, T; Secreto, C; Shanafelt, TD | 1 |
| Bardy-Bouxin, N; Bellet, M; Chow, L; Duvillié, L; Goss, P; Láng, I; Lebrun, F; Leip, E; Moy, B; Neven, P; Sarosiek, T; Turnbull, K; Xu, B; Zacharchuk, C | 1 |
1 trial(s) available for triazoles and bosutinib
| Article | Year |
|---|---|
Bosutinib in combination with the aromatase inhibitor letrozole: a phase II trial in postmenopausal women evaluating first-line endocrine therapy in locally advanced or metastatic hormone receptor-positive/HER2-negative breast cancer.
Topics: Aniline Compounds; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Female; Humans; Letrozole; Nitriles; Postmenopause; Protein Kinase Inhibitors; Quinolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Triazoles | 2014 |
1 other study(ies) available for triazoles and bosutinib
| Article | Year |
|---|---|
The novel receptor tyrosine kinase Axl is constitutively active in B-cell chronic lymphocytic leukemia and acts as a docking site of nonreceptor kinases: implications for therapy.
Topics: Aniline Compounds; Apoptosis; Axl Receptor Tyrosine Kinase; B-Lymphocytes; Benzocycloheptenes; Binding Sites; Coculture Techniques; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Myeloid Cell Leukemia Sequence 1 Protein; Nitriles; Phosphorylation; Protein Kinase Inhibitors; Protein Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Quinolines; Receptor Protein-Tyrosine Kinases; src-Family Kinases; Stromal Cells; Triazoles | 2011 |